Guarente Juliana, Tormey Christopher
Department of Pathology and Genomic Medicine, Pathology Residency Program, Thomas Jefferson University Hospital, 111 South 11th Street Gibbon Building, Room 8220, Philadelphia, PA 19107, USA.
Department of Laboratory Medicine, Transfusion Medicine Fellowship, Yale University School of Medicine, Yale-New Haven Hospital, 55 Park Street, Floor 3, Room 329D, New Haven, CT 06511, USA.
Clin Lab Med. 2023 Dec;43(4):669-683. doi: 10.1016/j.cll.2023.07.002. Epub 2023 Aug 11.
Patients with MDS often suffer from anemia, and less often thrombocytopenia, and thus are a frequently transfused population. Red blood cell (RBC) transfusion may be used to improve functional capacity and quality of life in this population, while platelet transfusion is typically used to decrease bleeding risk. Despite the frequency of transfusion in patients with MDS, there are few well-defined guidelines for RBC and platelet transfusion support in this patient population. Transfusion is not without risk-patients with MDS who are frequently transfused may develop alloantibodies to RBC antigens, which can lead to hemolytic transfusion reactions and delays in obtaining compatible RBCs. Regular communication between clinicians and blood bank physicians is crucial to ensure that patients with MDS receive the most appropriate blood products.
骨髓增生异常综合征(MDS)患者常伴有贫血,较少伴有血小板减少,因此是一个经常需要输血的群体。红细胞(RBC)输血可用于改善该群体的功能能力和生活质量,而血小板输血通常用于降低出血风险。尽管MDS患者输血频繁,但针对该患者群体的红细胞和血小板输血支持,几乎没有明确的指南。输血并非没有风险——经常输血的MDS患者可能会产生针对红细胞抗原的同种抗体,这可能导致溶血性输血反应,并延迟获得相容的红细胞。临床医生和血库医生之间的定期沟通对于确保MDS患者获得最合适的血液制品至关重要。